Abbott Laboratories (ABT) Quick Ratio (Acid-Test): 1.18
Is Abbott Laboratories’s quick ratio (acid-test) high or low?
Abbott Laboratories's quick ratio (acid-test) of 1.18 is in line with its 5-year average of 1.26, near the low end of its 5-year range (1.16–1.46).
The quick ratio (acid-test) for Abbott Laboratories (ABT) is 1.18 as of Wednesday, June 10, 2026. It is below its 12-month average by 2.07% (1.21).
ABT Quick Ratio (Acid-Test) Chart
ABT Average Quick Ratio (Acid-Test) Chart
ABT Current vs Average Quick Ratio (Acid-Test) Chart
ABT Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
1.18
QUICK RATIO (ACID-TEST) AVG TTM
1.21
QUICK RATIO (ACID-TEST) AVG 3Y
1.20
QUICK RATIO (ACID-TEST) AVG 5Y
1.26
QUICK RATIO (ACID-TEST) AVG 10Y
1.51
QUICK RATIO (ACID-TEST) AVG 15Y
1.50
QUICK RATIO (ACID-TEST) AVG 20Y
1.42
CURRENT VS TTM AVG
-2.07%
CURRENT VS 3Y AVG
-1.67%
CURRENT VS 5Y AVG
-6.35%
CURRENT VS 10Y AVG
-21.67%
CURRENT VS 15Y AVG
-21.37%
CURRENT VS 20Y AVG
-17.12%
ABT Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | — | 1.18 | 1.21 | 1.20 | 1.26 |
| Gilead Sciences, Inc. (GILD) | $151.21B | 1.31 | 1.38 | 1.29 | 1.26 |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 3.96 | 3.59 | 3.74 | 4.30 |
| Pfizer Inc. (PFE) | $146.36B | 0.87 | 0.90 | 0.87 | 0.95 |
| Danaher Corporation (DHR) | $130.25B | 1.51 | 1.28 | 1.37 | 1.36 |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 1.53 | 1.41 | 1.34 | 1.37 |
| Amgen Inc. (AMGN) | $183.75B | 0.90 | 0.93 | 1.02 | 1.14 |
| CVS Health Corporation (CVS) | $125.16B | 0.63 | 0.61 | 0.63 | 0.63 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.14 | 1.15 | 1.19 | 1.27 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 2.46 | 2.41 | 3.31 | 3.62 |
Liquidity Comparison
Quick Ratio
1.18
Excludes inventory
Current Ratio
1.58
Includes inventory
Abbott Laboratories Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Abbott Laboratories (ABT)?
- The quick ratio (acid-test) for ABT stock is 1.18.
- Is Abbott Laboratories's quick ratio (acid-test) high or low?
- Abbott Laboratories's quick ratio (acid-test) of 1.18 is in line with its 5-year average of 1.26, near the low end of its 5-year range (1.16–1.46).
- What is the TTM average quick ratio (acid-test) for Abbott Laboratories (ABT)?
- The TTM average quick ratio (acid-test) for ABT stock is 1.21.
- What is the 3Y average quick ratio (acid-test) for Abbott Laboratories (ABT)?
- The 3Y average quick ratio (acid-test) for ABT stock is 1.20.
- What is the 5Y average quick ratio (acid-test) for Abbott Laboratories (ABT)?
- The 5Y average quick ratio (acid-test) for ABT stock is 1.26.
- What is the 10Y average quick ratio (acid-test) for Abbott Laboratories (ABT)?
- The 10Y average quick ratio (acid-test) for ABT stock is 1.51.
- What is the 15Y average quick ratio (acid-test) for Abbott Laboratories (ABT)?
- The 15Y average quick ratio (acid-test) for ABT stock is 1.50.
- What is the 20Y average quick ratio (acid-test) for Abbott Laboratories (ABT)?
- The 20Y average quick ratio (acid-test) for ABT stock is 1.42.
Abbott Laboratories Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 1.18 |
| 2024-12-31 | 1.23 |
| 2023-12-31 | 1.16 |
| 2022-12-31 | 1.23 |
| 2021-12-31 | 1.46 |
| 2020-12-31 | 1.30 |
| 2019-12-31 | 1.04 |
| 2018-12-31 | 1.20 |
| 2017-12-31 | 1.86 |
| 2016-12-31 | 3.65 |
| 2015-12-31 | 1.26 |
| 2014-12-31 | 1.20 |
| 2013-12-31 | 1.74 |
| 2012-12-31 | 2.07 |
| 2011-12-31 | 1.32 |
| 2010-12-31 | 1.11 |
| 2009-12-31 | 1.54 |
| 2008-12-31 | 1.23 |
| 2007-12-31 | 1.22 |
| 2006-12-31 | 0.71 |
| 2005-12-31 | 1.19 |
| 2004-12-31 | 1.19 |
| 2003-12-31 | 0.99 |
| 2002-12-31 | 0.95 |
| 2001-12-31 | 0.78 |
| 2000-12-31 | 1.31 |
| 1999-12-31 | 1.09 |
| 1998-12-31 | 0.83 |
| 1997-12-31 | 0.75 |
| 1996-12-31 | 0.75 |
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford